



(86) Date de dépôt PCT/PCT Filing Date: 2000/02/04
(87) Date publication PCT/PCT Publication Date: 2000/08/10
(45) Date de délivrance/Issue Date: 2009/02/03
(85) Entrée phase nationale/National Entry: 2001/07/18
(86) N° demande PCT/PCT Application No.: DK 2000/000049
(87) N° publication PCT/PCT Publication No.: 2000/045847
(30) Priorités/Priorities: 1999/02/05 (US60/118,896);
1999/02/05 (DK PA 1999 00115)

(51) Cl.Int./Int.Cl. *A61K 39/35* (2006.01),
A61P 37/08 (2006.01), *A61K 39/39* (2006.01)
(72) Inventeurs/Inventors:
IPSEN, HANS HENRIK, DK;
ULDAL RAHBEK, JANNE, DK
(73) Propriétaire/Owner:
ALK-ABELLO A/S, DK
(74) Agent: RIDOUT & MAYBEE LLP

(54) Titre : NOUVEAU SYSTEME D'ADMINISTRATION PAR LES MUQUEUSES
(54) Title: NOVEL MUCOSAL DELIVERY SYSTEM

(57) **Abrégé/Abstract:**

Compositions for the delivery of biologically interactive substances via a mucosal membrane, vaccines and formulations as well as mucosal delivery systems comprising an oxygen-containing metal salt are described herein. Furthermore, methods of generating immune responses, vaccinations and treatments of vertebrates, including human beings, as well as methods of treating, preventing or alleviating allergic reactions are described. A process for preparing the compositions, the vaccines, and the formulations is disclosed. The compositions and delivery systems are useful in a wide range of applications.



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 47/02	A1	(11) International Publication Number: WO 00/45847 (43) International Publication Date: 10 August 2000 (10.08.00)
(21) International Application Number: PCT/DK00/00049 (22) International Filing Date: 4 February 2000 (04.02.00) (30) Priority Data: PA 1999 00115 5 February 1999 (05.02.99) DK 60/118,896 5 February 1999 (05.02.99) US (71) Applicant (for all designated States except US): ALK-ABELLÓ A/S [DK/DK]; Bøge Allé 6-8, DK-2970 Hørsholm (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): IPSEN, Hans, Henrik [DK/DK]; Egevej 16, DK-3400 Hillerød (DK). ULDAL RAHBK, Janne [DK/DK]; Brandbakken 5A, DK-2840 Holte (DK). (74) Agent: HOFMAN-BANG A/S; Hans Bekkevolds Allé 7, DK-2900 Hellerup (DK).		(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: NOVEL MUCOSAL DELIVERY SYSTEM (57) Abstract Compositions for the delivery of biologically interactive substances via a mucosal membrane, vaccines and formulations as well as mucosal delivery systems comprising an oxygen-containing metal salt are described herein. Furthermore, methods of generating immune responses, vaccinations and treatments of vertebrates, including human beings, as well as methods of treating, preventing or alleviating allergic reactions are described. A process for preparing the compositions, the vaccines, and the formulations is disclosed. The compositions and delivery systems are useful in a wide range of applications.		

NOVEL MUCOSAL DELIVERY SYSTEM

The present invention relates to compositions for the delivery of biologically interactive substances via a mucosal membrane, to vaccines and formulations as well as a mucosal delivery system comprising an oxygen-containing metal salt. In other aspects, the present invention relates to methods of generating immune responses, vaccinations and treatments of vertebrates, including human beings, as well as methods of treating, preventing or alleviating allergic reactions. Furthermore, the present invention concerns the use of oxygen-containing metal salts for preparing mucosal delivery systems, and the use of antibodies raised by administering a vaccine according to the invention. Furthermore, the present invention relates to a process for preparing the compositions, the vaccines or the formulations, as well as the products obtainable by the process.

20 BACKGROUND OF THE INVENTION

Diseases and various conditions are treated in different ways. Sometimes surgery is the only option, but most conditions are at least at first treated by administering a medicament to the patient curing or alleviating the disease and/or the symptoms. Medicaments are also given as prophylactic treatment.

Sometimes the active compound of a medicament can only be formulated as injectables, or the active compound has little or no effect unless administered parenterally. This is in particular true in the case of many vaccine antigens.

35 Parenteral treatment must most often be performed by a physician. The appointment requirement is by patients

experienced as inconvenient. Furthermore, the injections themselves are usually experienced as unpleasant, all together causing poor patient compliance.

- 5 Several parenteral delivery systems are known in the art. They are well described in a large number of textbooks.

Several attempts have been made to prepare mucosal formulations comprising an active compound which is
10 unable to pass the mucosal membrane, thus, avoiding the parenteral route. However, the efforts have not been very successful as evidenced by the very restricted numbers of such products on the market. This is i.a. due to poor bioavailability at the mucosal biomembrane.

15

OBJECT OF THE INVENTION

The object of the present invention is to provide a delivery system for delivery of biologically interactive
20 substances via a mucosal membrane of a vertebrate. The mucosal delivery system is useful in the formulation of compositions for delivery of biologically interactive substances via the mucosal membrane. A wide range of other applications making use of the mucosal delivery
25 system and of the compositions is envisaged. In particular, the mucosal delivery system may be incorporated in a vaccine, thus avoiding conventional parenteral vaccination.

30 Thus, in accordance with the present invention, delivery of biologically interactive substances via the mucosal membrane is possible in an easy, efficient way which should further be acceptable to all patients.

35 From WO 94/21288 (ref. 1), compositions comprising an admixture of a colloidal metal and an immunologically

toxic biologically active factor are known. The toxic biologically factor is selected from cytokines, growth factors and glycoproteins from infectious organisms, e.g. IL-1, IL-2, IL-4, IL-6, IL-8, staphylococcal enterotoxin B, and Macrophage Colony-Stimulating Factor (CSF). The compositions may further comprise an adjuvant such as Freund's complete or incomplete adjuvant, liposomes, muramyl dipeptide or alum. The document further describes a method of administering a toxic biologically-active factor yielding an immunological response to the biologically-active factor while reducing toxic side effects resulting from the biologically-active factor. The composition is preferably administered intravenously, intramuscularly or subcutaneously.

15

In WO 95/05194 (ref. 2), the use of Hepatitis A virus capsid or a mucosally immunogenic fragment or epitope thereof for the manufacture of a mucosal vaccine composition is described. The mucosal vaccine composition is administered to a mucosal surface of a patient to induce production of serum Immunoglobulin G antibody against Hepatitis A. The composition is formulated for delivery to the nasal or bronchial mucosa.

25 From JP 65008152 B (ref. 3), oral vaccines are known. The oral vaccines are prepared from bacteria, bacterial toxins, viruses, rickettsia, etc. by (1) inactivation, (2) precipitation by addition of astringents, (3) drying the precipitate and conversion into tablets. Thus, the object is to provide a dry tablet, for which the gastric fluid does not inactivate the product. In the abstract, there is no mentioning of a delivery system ensuring delivery of the immunogenic compound via the mucosal biomembrane.

35

From GB 2 195 996 (ref. 4), a complex of tea-leaf extract containing the organic compound (-)-epigallocatechin gallate as principal component and active aluminium hydroxide is known. The complexes are stated to possess anti-ulcer activity, anti-peptic and antacid activity. The complex formulated in a composition may suitably be administered orally. Although the composition is intended for oral use, the purpose of this is not delivery of a substance via the mucosal membrane. The target is the interior of the stomach. Thus, mucosal delivery is not disclosed or anticipated.

From GB 1 078 879 (ref. 5), an antacid composition comprising a colloidal aqueous ingestible suspension of aluminium hydroxide and at least one digestive enzyme adsorbed on the aluminium hydroxide is known. The composition is intended for oral use. The composition is for the treatment of stomach upset, indigestion, hyperchlorhydria, peptic ulcer and similar conditions. Although the composition is intended for oral use, the purpose of this is not delivery of a substance via the mucosal membrane. The target is the interior of the stomach. Thus, mucosal delivery is not disclosed or anticipated.

From FR 2 143 588 (ref. 6), a vaccine for immunisation of aquatic birds against goose hepatitis is known. The vaccine may contain aluminium hydroxide as an adjuvant. The vaccine is to be administered by injection. Delivery via a mucosal membrane is not disclosed or anticipated.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the IgG1 response on day 35 for mice immunised p.o. with *Tetanus toxoid* suspended with Alhydrogel®.

Figure 2 shows the IgG1 response on day 35 for mice immunised p.o. with *Tetanus toxoid* without Alhydrogel[®] carrier.

5

Figure 3 shows the IgG1 response on day 35 for mice immunised i.p. with *Tetanus toxoid* (control group).

Figure 4 shows the IgG2a response on day 35 for mice immunised p.o. with *Tetanus toxoid* suspended with Alhydrogel[®].

Figure 5 shows the IgG2a response on day 35 for mice immunised p.o. with *Tetanus toxoid* without Alhydrogel[®] carrier.

Figure 6 shows the IgG2a response on day 35 for mice immunised i.p. with *Tetanus toxoid* (control group).

Figure 7 shows the IgG1 response on day 56 for mice immunised p.o. with *Tetanus toxoid* suspended with Alhydrogel[®].

Figure 8 shows the IgG1 response on day 56 for mice immunised p.o. with *Tetanus toxoid* without Alhydrogel[®] carrier.

Figure 9 shows the IgG1 response on day 56 for mice immunised i.p. with *Tetanus toxoid* (control group).

30

Figure 10 shows the IgG2a response on day 56 for mice immunised p.o. with *Tetanus toxoid* suspended with Alhydrogel[®].

Figure 11 shows the IgG2a response on day 56 for mice immunised p.o. with *Tetanus toxoid* without Alhydrogel[®] carrier.

- 5 Figure 12 shows the IgG2a response on day 56 for mice immunised i.p. with *Tetanus toxoid* (control group).

Figure 13 shows the IgG1 response on day 70 for mice immunised p.o. with *Tetanus toxoid* suspended with
10 Alhydrogel[®].

Figure 14 shows the IgG1 response on day 70 for mice immunised p.o. with *Tetanus toxoid* without Alhydrogel[®] carrier.

15

Figure 15 shows the IgG1 response on day 70 for mice immunised i.p. with *Tetanus toxoid* (control group).

Figure 16 shows the IgG2a response on day 70 for mice
20 immunised p.o. with *Tetanus toxoid* suspended with Alhydrogel[®].

Figure 17 shows the IgG2a response on day 70 for mice immunised p.o. with *Tetanus toxoid* without Alhydrogel[®]
25 carrier.

Figure 18 shows the IgG2a response on day 70 for mice immunised i.p. with *Tetanus toxoid* (control group).

30 Figure 19 shows the IgG1 response on day 70 for mice immunised p.o. with *Phleum pratense* suspended with Alhydrogel[®].

Figure 20 shows the IgG1 response on day 70 for mice
35 immunised p.o. with *Phleum pratense* without the Alhydrogel[®] carrier.

Figure 21 shows the IgG1 response for mice immunised i.p. with *Phleum pratense* (control group).

- 5 Figure 22 shows the IgG2a response on day 70 for mice immunised p.o. with *Phleum pratense* suspended with Alhydrogel®.

- 10 Figure 23 shows the IgG2a response on day 70 for mice immunised p.o. with *Phleum pratense* without the Alhydrogel® carrier.

- 15 Figure 24 shows the IgG2a response for mice immunised i.p. with *Phleum pratense* (control group).

- Figure 25 shows the specific Ig response on day 106 for mice immunised s.c. with *Phleum pratense* on day 0, 21, 22, 23.

- 20 Figure 26 shows the specific Ig response on day 106 for mice immunised s.c. with *Phleum pratense* on day 0 and p.o. on day 21, 22, 23.

- 25 Figure 27 shows the specific Ig response on day 106 for mice immunised s.c. with *Phleum pratense* on day 0 and p.o. with placebo on day 21, 22, 23.

DETAILED DESCRIPTION OF THE INVENTION

- 30 As mentioned above, several attempts have been made to prepare formulations suitable for delivery of substances through the mucosal membrane. The attempts have not been very successful. Either the preparations were not effective, or the efficacies have been reduced, when
35 compared to other routes. Thus, the very limited number of commercially available mucosal delivery formulations

on the market indicates the difficulties met when developing such pharmaceutical compositions. It has now surprisingly been found that delivery via the mucosal membrane is in fact possible using a mucosal delivery
5 system as claimed herein.

Thus, in one aspect, the present invention relates to a composition for the delivery of a biologically interactive substance via a mucosal membrane of a
10 vertebrate comprising (1) at least one biologically interactive substance, and (2) a mucosal delivery system comprising an oxygen-containing metal salt.

The term "biologically interactive substance" refers to
15 any substance that has a biological effect in itself, or any substance that interacts with or influence other substances, reactions in the body and/or organs resulting in a biological effect. It could also be a substance, that when present in one compartment exerts a biological
20 effect in a different or the same biological compartment.

A wide range of biologically interactive substances may be applied in the present invention. Examples of such substances are immunogenic substances, nutritional
25 substances, medicaments, and genetic material, as well as analogues or derivatives thereof.

Examples of immunogenic substances are antigens, allergens, allergoids, peptides, haptens, carbohydrates,
30 peptide nucleic acids (PNAs, a sort of synthetic genetic mimic), and viral or bacterial material as well as analogues or derivatives thereof. Examples of nutritional substances are vitamins, enzymes, trace elements, and trace minerals as well as analogues or derivatives
35 thereof. Examples of medicaments are antibodies, antibiotics, peptides, salts, hormones, hemolytics,

haemostatics, enzymes, enzyme inhibitors, psychoactive drugs, opiates, and barbiturates, as well as analogues or derivatives thereof. Examples of genetic material are DNA, RNA and PNA.

5

In the present context, the term analogues or derivatives is intended to include modified forms of the biologically interactive substance. The modification can be made by chemical modification or synthetic modification, e.g. by
10 biotinylation, deamination, maleination, substitution of one or more amino acids, by cross-linking, by glycosylation, or by other recombinant technology. The term is also intended to include natural-occurring mutations, isoforms and retroinverse analogues.

15

The efficacy of the compositions, formulations and vaccines of the invention is related to the mucosal delivery system, which comprises at least one oxygen-containing metal salt.

20

The oxygen-containing metal salts can be characterised by a variety of physical-chemical parameters like adsorption, solubility and dissolution properties, ionic charge measured as the isoelectric point pI (pH where the
25 net charge of the substance is zero for a dissociationable compound), dissociation constants, complex coordination, electronic configurations, valence, bonding orbitals and antibonding orbitals, depot properties, adhesion properties, surface characteristics, particle
30 characteristics, and adjuvanticity.

Several features of the metal salts are believed to be important for or connected to the observed beneficial effects of the mucosal delivery system herein described.
35 It should be understood that the hypotheses below should in no way be limiting to the scope of the invention.

Common features for the delivery systems are that they conserve, retain, deliver, and/or enhance the effect of the biological interactive substance in a form available
5 for delivery via the mucosal membrane.

It is believed that the substance of biological value (the biologically interactive substance) is adsorbed (or coupled) to the oxygen-containing metal salt, and this
10 adsorption contributes to the efficacy of the mucosal delivery system, compositions, formulations and vaccines, respectively. Several factors may be important or influence the adsorption between the biological interactive substance and the oxygen-containing metal
15 salt (see e.g. P.M. Callahan et al., Pharmaceutical Research Vol. 8, No. 7, 851-858 (1991) (ref. 7), and Vaccine Design. The Subunit and Adjuvant Approach (ref. 8), incorporated herein by reference).

20 These include pH, the length of time the adsorption reaction is carried out for, mixing conditions, concentrations of the various components in the formulations, compositions and vaccines, containers, temperature, storage, buffer and excipients.

25 It has been found that in some aspects of the invention the adsorption of the biological interactive substance is influenced by the net/overall charge of the metal salt and the charge of the biological interactive substances,
30 both which are pH dependent.

Metal salt pI may vary (from salt to salt) typically from 2-11 resulting in different optimal coupling pH intervals, Both acidic, alkaline and neutral conditions
35 may be employed, e.g. for commonly used forms of

aluminium hydroxide pH 6-10 is used, more acidic intervals are used for aluminium acetate and more alkaline for magnesium hydroxide.

- 5 The pI, when relevant, of the dissociationable biological interactive substances may likewise vary within the range of 2-11, e.g., for protein antigens the pI value is often in the range of 4-9.
- 10 Thus, adsorption can be carried out over a wide pH range, but preferably conditions are chosen where pH is between the pI of the oxygen-containing metal salt and the average pI of the biological interactive substances to be adsorbed. E.g. effective adsorption has been obtained at
- 15 pH 8.3, where the pI of the oxygen-containing metal salt, a form of aluminium hydroxide, is 9.2 and the pI of the biological interactive substance, a protein mixture containing *Phleum pratense*, lies within the range of 4-9 for the proteins.
- 20 For several of the oxygen-containing metal salts (e.g. $\text{Al}(\text{OH})_3$, AlPO_4) a high surface area gives a high adsorptive capacity for the biologically interactive substances.
- 25 The degree of adsorption will also vary with the metal salt used, and the working concentration of this, e.g. the working concentration may vary for Al^{3+} , preferably 0.035-1000 mg/ml formulated as aluminium hydroxide, most
- 30 preferably 0.35-100 mg/ml.

The working concentration of the biological interactive substance may further influence the adsorption to the

metal salt and can vary widely depending on the substance. For proteins, a working concentration range within 0.01 mg/ml-100 mg/ml is preferred, most preferably within 0.01-10 mg/ml.

5

The interaction between the delivery system and the biological interactive substance is also influenced by the ratio of these, during the adsorption procedure, as well as in the final formulation. The ratio (the amount
10 of biological interactive substance/the amount of mucosal delivery system on a weight basis) should be found in the above-mentioned ranges. These may accordingly vary within 0.01-100,000, preferably within 0.01-100, most preferably within 1-20.

15

The final formulation should be of such a composition that the amount of the biological substance adsorbed to the oxygen-containing metal salt is in the range of 5-99%, more preferably 10-99% of the added amount.

20

Further the adsorption has been found to be influenced by the type of buffer system chosen (e.g. NaCl, NaHCO₃, amines), the buffer salt concentration (e.g. 0-40% NaCl) and the presence of excipients (e.g. glycerol 0-70%).

25

The efficacy of the coupling is dependent on the length of time the reaction is carried out and temperature. Preferably adsorption can be obtained at temperatures between 4-45°C, more preferably between 4-20°C. The
30 preferred length of time for coupling is 0.1-48 hours, more preferably 12-24 hours.

Containers for coupling and storage of the product can be glass and different polymeric materials. It is important to choose a container, which does not adsorb the product. E.g. glass of pharmaceutical grade for proteins.

5

A further feature believed to be of importance is the solubility of the oxygen-containing metal salts. Preferred oxygen-containing metal salts are water insoluble as well as oxygen-containing metal salts having
10 a water solubility of not more than 0.01 mol/l at 25°C. More preferably insoluble oxygen-containing metal salts or oxygen-containing metal salts with a water solubility of not more than 0.005 mol/l at 25°C.

15 The oxygen-containing metal salt may further have a depot effect. A depot effect means that the biological interactive substance will be released gradually from the formulation, composition, vaccine or mucosal delivery system. The biological interactive active substance will
20 thus be retained with the oxygen-containing metal salt(s), i.e. with the mucosal delivery system and released gradually therefrom. This is believed to have a number of beneficial effects, e.g. prolonged stimulation, beneficial drug release, and protection of the biological
25 interactive substances against environmental conditions. It is further believed that the oxygen-containing metal salt of the delivery system may possess certain entrapment properties, thus retaining the substance to be delivered via the mucosal membrane.

30

Another feature of the invention is the protection of the biological interactive substance. Either by maintaining the ideal pH for the biological interactive substance in the microenvironment, thus preventing acid degradation or

protecting against enzymatic degradation thereby allowing the substance to be delivered via the mucosal membrane.

Furthermore, some of the oxygen-containing metal salts
5 have a buffer capacity. This may result in an in vivo microenvironment within the delivery system, which protects the biologically interactive substance from the degradable environment. This may e.g. be an advantage in the stomach or intestine where there is a risk of acid
10 and enzymatic degradation, respectively.

A further feature of the oxygen-containing metal salt(s) of the mucosal delivery system can be their capability to adhere to the mucosal membrane, or the effect they may
15 exert on the gastrointestinal movement, e.g. slowing it down. The extended time of passage through the intestine may be beneficial due to the enhanced possibility of prolonging the time allowed for interaction of the biological interactive substance with the target tissue
20 (mucosal membrane), thereby leading to increased transport of the biological interactive substances via the mucosal membrane. Also the muco-adhesive properties of the oxygen-containing metal salt(s)/mucosal delivery system may allow exertion of other functions, e.g.,
25 mucosal adjuvant properties, which can result in a faster on-set and effect of the desired response. Different compounds with adjuvant properties are described in e.g. ref. 8, Chapter 7.

30 It is further believed that the mucosal delivery system of the invention/the oxygen-containing metal salt(s) can be designed to have specific preference for specific mucosal tissues e.g. GALT and Peyers patch, further enhancing the delivery of the active substances at a
35 relevant target site (mucosal tissue) as in EP 266 119 (ref. 9). For several of the oxygen-containing metal

salts (e.g. $\text{Al}(\text{OH})_3$, AlPO_4 , Ca_3PO_4) the particle size range between 0.5-15 μm .

5 It has been observed, that an interaction between the biological interactive substances and the immunocompetent tissues in the gastrointestinal tract can take place, resulting in cellular and ultimately humoral systemic responses.

10 The mucosal delivery system of the invention is for the delivery of a biologically interactive substance via a mucosal membrane. Preferred mucosal membranes include the nasal mucosal membrane, the gastrointestinal mucosal membrane, and the sublingual mucosal membrane.

15

Examples of suitable oxygen-containing metal salts are e.g. those, wherein the cation is selected from Al, K, Ca, Mg, Zn, Ba, Na, Li, B, Be, Fe, Si, Co, Cu, Ni, Ag, Au, and Cr.

20

The anion of the oxygen-containing compound may be an organic or inorganic anion, or a combination of organic and inorganic anions. Examples of suitable oxygen-containing metal salts are e.g. those, wherein the anion
25 selected from sulphates, hydroxides, phosphates, nitrates, iodates, bromates, carbonates, hydrates, acetates, citrates, oxalates, and tartrates, as well as mixed forms thereof. The oxygen-containing metal salts further comprise coordination complexes. A definition of
30 coordination complexes is given in e.g. The Handbook of Chemistry and Physics 56 Ed., Section B, Chapter 7 (1975-76) (ref. 10).

Within the present context, the expression mixed forms is
35 intended to include combinations of the various anions as well as combinations with e.g. chlorides, and sulphides.

Although the delivery system comprises an oxygen-containing metal salt, it is contemplated that another Group VIA atom such as S, Se or Te could substitute the oxygen.

5

The oxygen-containing metal salt to be used in accordance with the invention may be any oxygen-containing metal salt providing the desired effect when formulated into the mucosal delivery system. Examples of such oxygen-containing substances are aluminium hydroxide, aluminium phosphate, aluminium sulphate, aluminium acetate, potassium aluminium sulphate, calcium phosphate, calcium tartrate, Maalox (mixture of aluminium hydroxide and magnesium hydroxide), beryllium hydroxide, zinc hydroxide, zinc carbonate, zinc sulphate, and barium sulphate.

Most preferred are aluminium hydroxide, aluminium phosphate, aluminium acetate, calcium phosphate, calcium tartrate and zinc sulphate.

The biologically interactive substances may preferably be selected from

nutritional substances like vitamins such as vitamin B12, vitamin B6, vitamin A, vitamin E, vitamin D, vitamin D3, iron, and folic acid;

enzymes such as urokinase, TPA (tissue plasminogen activator), coagulation Factor VIII, and streptokinase; immunogenic substances such as natural, recombinant or modified proteins or fragments thereof, antigens, allergens (cf. below), allergoids, peptides, haptens conjugated on a suitable carrier like KLH (key hole limpet hemocyanin) or *Tetanus toxoid*, carbohydrates, optionally inactivated or attenuated bacteria or virus as

well as components thereof, RNA, DNA, PNA, parasites or retroviruses, parasitic material, mycoplasma, or toxins, e.g. such derived from

- 5 Tetanus toxoid, Diphtheria toxoid, Cholera toxin A and B subunits, Rubella, Rhabdovirus (rabies), Myxoviruses, Paramyxoviruses like parainfluenza virus, mumps and measles, Picornaviruses like poliovirus, coxsackievirus, echovirus and rhinovirus, Reoviruses, Poxviruses like
- 10 small pox virus, Vaccinia virus and cowpox virus, Papovaviruses like polyoma virus, papilloma virus and SV-40, Adenoviruses, EBV like mononucleosis virus, Parvoviruses like HPV B19, Herpes viruses like Herpes simplex virus, and Herpes zoster virus (Varicella virus),
- 15 Cytomegalovirus (CMV), Arboviruses like yellow fever and Dengue fever, Retroviruses like HIV, Hepatitis viruses like Hepatitis A, Hepatitis B and Hepatitis C, Haemophilus influenzae type B, Mycobacterium like M. tuberculosis, M. bovis, M. africanum, M. microti, M.
- 20 avium, M. intracellulare, M. kansasii, M. gordonae, M. paratuberculosis, and M. leprae, Borrelia spp. like B. burgdorferi, in particular B. burgdorferi sensu lato and B. burgdorferi sensu stricto, B. garinii, B. afzelii, B. duttoni and B. recurrentis, Bordetella pertussis
- 25 (whooping cough), Salmonella spp. like S. typhimurium and S. typhi, Treponema spp. like T. pallidum, Leptospira spp., Campylobacter spp. like C. jejuni, Helicobacter spp. like H. pylori, Pseudomonas spp., Legionella spp., Neisseria spp. like N. gonorrhoea and N. meningitidis,
- 30 Chlamydia spp. like C. trachomatis, C. pneumonia and C. psittaci, Enterobacter spp., Klebsiella spp., Yersinia spp., Vibrio spp. like Vibrio cholerae, Gardnerella spp., Rickettsia spp., Clostridium spp. like C. difficile, C. botulinum and C. tetani, Lactobacillus spp., Listeria
- 35 spp., and Mycoplasma spp. like M. pneumoniae M. hominis, Plasmodium falciparum, and Leishmania donovani,

moulds and fungi such as Cladospodium, Alternaria, Aspergillus, Basidiomycetes, Candida albicans, and Penicillium,

5

allergoids such as glutaraldehyde modified allergen complexes;

medicaments such as β -lactams e.g. penicillin, sulpham-
10 containing preparations, enzymes, enzyme inhibitors e.g. acetylcholin esterase inhibitor, hormones e.g. LHRH, estrogen, insulin and human growth hormone, haemolytics/haemostatics e.g. heparin, and erythropoietin α or β , psychoactive drugs e.g. lithium, opiates e.g.
15 morphine, and barbiturates;

genetic material such as DNA, RNA, and PNA;

other medicaments like cancer-related compounds such as
20 TNF α , LHRH analogues, and cytostatics;

other compounds such as sugars, mannans and lectins;
as well as analogues or derivatives thereof.

25 The composition according to the invention facilitates delivery via a mucosal membrane anywhere in the body. Thus, the composition can be administered via the oral, nasal, vaginal, sublingual, ocular, rectal, urinal, intramammal, pulmonal, otolar (i.e. via the ear) or
30 buccal route.

The composition may suitably be in the form of a spray, an aerosol, a mixture, tablets (entero- or not-enterocoated), capsule (hard or soft, entero- or not-
35 enterocoated), a suspension, a dispersion, granules, a powder, a solution, an emulsion, chewable tablets,

tablets for dissolution, drops, a gel, a paste, a syrup,
a cream, a lozenge (powder, granulate, tablets), an
instillation fluid, a gas, a vapour, an ointment, a
stick, implants (ear, eye, skin, nose, rectal, or
5 vaginal), intramammary preparations, vagitories,
suppositories, or uteritories.

In another aspect, the present invention relates to a
vaccine for the delivery of an immunogenic substance via
10 a mucosal membrane of a vertebrate comprising (1) at
least one immunogenic substance and (2) a mucosal
delivery system comprising an oxygen-containing metal
salt. The vaccine may preferably be such wherein the
immunogenic substance is selected from natural,
15 recombinant or modified proteins or fragments thereof,
antigens, allergens, allergoids, haptens, peptides,
carbohydrates, optionally inactivated or attenuated
virus, optionally inactivated or attenuated bacteria,
RNA, DNA, PNA, retroviruses, parasites or parasitic
20 material, mycoplasma, and toxins, as well as analogues or
derivatives thereof. The vaccine may be in the form of a
spray, an aerosol, a mixture, tablets (entero- and not-
enterocoated), capsule (hard and soft, entero- and not-
enterocoated), a suspension, a dispersion, granules, a
25 powder, a solution, an emulsion, chewable tablets,
tablets for dissolution, drops, a gel, a paste, a syrup,
a cream, a lozenge (powder, granulate, tablets), an
instillation fluid, a gas, a vapour, an ointment, a
stick, implants (ear, eye, skin, nose, rectal, and
30 vaginal), intramammary preparations, vagitories,
suppositories, or uteritories, suitable for delivery via
the oral, nasal, vaginal, sublingual, ocular, rectal,
urinal, intramammal, pulmonal, otolar, or buccal route.
The vaccine may e.g. be suitable for vaccination, or
35 allergy vaccination (desensitisation), prevention or
alleviation of allergic conditions.

The present invention also relates to a formulation for the delivery of a nutritional substance via a mucosal membrane of a vertebrate comprising (1) at least one
5 nutritional substance and (2) a mucosal delivery system comprising an oxygen-containing metal salt. The nutritional substance is preferably selected from vitamins, salts, enzymes, trace elements, and trace minerals. The formulation may preferably be in the form
10 of a spray, an aerosol, a mixture, tablets (entero- or not-enterocoated), capsule (hard or soft, entero- or not-enterocoated), a suspension, a dispersion, granules, a powder, a solution, an emulsion, chewable tablets, tablets for dissolution, drops, a gel, a paste, a syrup,
15 a cream, a lozenge (powder, granulate, tablets), an instillation fluid, a gas, a vapour, an ointment, a stick, implants (ear, eye, skin, nose, rectal, or vaginal), intramammary preparations, vagitories, suppositories, or uteritories, suitable for delivery via
20 the oral, nasal, vaginal, sublingual, ocular, rectal, urinal, intramammal, pulmonal, otolar or buccal route.

In a further aspect, the present invention relates to a formulation for the delivery of a medicament via a
25 mucosal membrane of a vertebrate comprising (1) at least one medicament and (2) a mucosal delivery system comprising an oxygen-containing metal salt. The medicament may preferably be selected from antibodies, antibiotics, peptides and derivatives thereof, salts,
30 hormones, hemolytics, and haemostatics. In a preferred embodiment, the medicament is selected from β -lactams e.g. penicillin, sulpha-containing preparations, enzyme inhibitors e.g. acetylcholin esterase inhibitor, hormones e.g. LHRH, estrogen, insulin and human growth hormone,
35 hemolytics/haemostatics e.g. heparin, and erythropoietin α or β , psychoactive drugs e.g. lithium, opiates e.g.

morphine, and barbiturates. The formulation may suitably be in the form of a spray, an aerosol, a mixture, tablets (entero- or not-enterocoated), capsule (hard or soft, entero- or not-enterocoated), a suspension, a dispersion, 5 granules, a powder, a solution, an emulsion, chewable tablets, tablets for dissolution, drops, a gel, a paste, a syrup, a cream, a lozenge (powder, granulate, tablets), an instillation fluid, a gas, a vapour, an ointment, a stick, implants (ear, eye, skin, nose, rectal, or 10 vaginal), intramammary preparations, vagitories, suppositories, or uteritories, suitable for administration via oral, nasal, vaginal, sublingual, ocular, rectal, urinal, intramammal, pulmonal, otolar or buccal route.

15

In yet a further aspect, the present invention relates to a formulation for the delivery of genetic material via a mucosal membrane of a vertebrate comprising (1) genetic material, viral material or bacterial material, and (2) a 20 mucosal delivery system comprising an oxygen-containing metal salt. The genetic material may preferably be selected from RNA, DNA, and PNA, as well as analogues or derivatives thereof. The formulation may suitably be in the form of a spray, an aerosol, a mixture, tablets 25 (entero- or not-enterocoated), capsule (hard or soft, entero- or not-enterocoated), a suspension, a dispersion, granules, a powder, a solution, an emulsion, chewable tablets, tablets for dissolution, drops, a gel, a paste, a syrup, a cream, a lozenge (powder, granulate, tablets), 30 an instillation fluid, a gas, a vapour, an ointment, a stick, implants (ear, eye, skin, nose, rectal, or vaginal), intramammary preparations, vagitories, suppositories, or uteritories, suitable for administration via the oral, nasal, vaginal, sublingual, 35 ocular, rectal, urinal, intramammal, pulmonal, otolar, or buccal route.

A mucosal delivery system for delivery of a biologically interactive substance via a mucosal membrane of a vertebrate also forms part of the present invention. Such
5 delivery system comprises at least one oxygen-containing metal salt. The metal salt may be any oxygen-containing metal salt providing the desired effect when formulated into the delivery system. In a preferred embodiment, the
10 cation of the oxygen-containing metal salt is selected from Al, K, Ca, Mg, Zn, Ba, Na, Li, B, Be, Fe, Si, Co, Cu, Ni, Ag, Au, and Cr. In a preferred embodiment, the anion of the oxygen-containing metal salt is selected from sulphates, hydroxides, phosphates, nitrates, iodates, bromates, carbonates, hydrates, acetates,
15 citrates, oxalates, and tartrates, and mixed forms thereof. Examples of such oxygen-containing substances are aluminium hydroxide, aluminium phosphate, aluminium sulphate, aluminium acetate, potassium aluminium sulphate, calcium phosphate, calcium tartrate, Maalox
20 (mixture of aluminium hydroxide and magnesium hydroxide), beryllium hydroxide, zinc hydroxide, zinc carbonate, zinc sulphate and barium sulphate.

The mucosal delivery system may preferably be in the form
25 of a spray, an aerosol, a mixture, tablets (entero- or not-enterocoated), capsule (hard or soft, entero- or not-enterocoated), a suspension, a dispersion, granules, a powder, a solution, an emulsion, chewable tablets, tablets for dissolution, drops, a gel, a paste, a syrup,
30 a cream, a lozenge (powder, granulate, tablets), an instillation fluid, a gas, a vapour, an ointment, a stick, implants (ear, eye, skin, nose, rectal, or vaginal), intramammary preparations, vagitories, suppositories, or uteritories, suitable for
35 administration via the oral, nasal, vaginal, sublingual,

ocular, rectal, urinal, intramammal, pulmonal, otolar, or buccal route.

5 The present invention also concerns a method for the delivery of a biologically interactive substance via a mucosal membrane of a vertebrate comprising administering a composition as described above to the vertebrate, including a mammal and in particular a human being.

10 The present invention has a number of important applications.

An example of an important field of applications is the field of vaccination. One of the major achievements of
15 the scientists has been the development of vaccines for preventing life-threatening diseases like e.g. Tetanus or tuberculosis. Vaccination is traditionally performed by the subcutaneous or intramuscular route. By the present invention, vaccination via a mucosal route is indeed
20 possible. In accordance herewith, the present invention relates to a method of generating or altering an immune response in a vertebrate, including a human being, which method comprises administering to the vertebrate a vaccine as defined herein. Furthermore, the invention
25 relates to vaccination or treatment of a vertebrate, including a human being, comprising administering to the vertebrate a vaccine, a formulation, or a composition as defined herein.

30 In the present context, the term immune response includes specific antibody and/or B- and T-cell activity, the antibodies being from the classes IgA, IgD, IgE, IgG and IgM as well as subclasses thereof. The term is also intended to include other serum or tissue components.

A response may with regard to T-cell activity be regarded as mixed or skewed towards a Th₁ or Th₂ type because of adjuvanticity (ref. 8, Chapter 7). Humorally, it may result in serologic and/or secretory antibodies.

5

The concept of vaccination is based on two fundamental characteristics of the immune system, namely specificity and memory. Vaccination will prime the immune system of the recipient, and upon repeated exposure to the same
10 proteins the immune system will be in a position to respond more rigorously to the challenge of for example a microbial infection. Vaccines are mixtures of proteins intended to be used in vaccination for the purpose of generating such a protective immune response in the
15 recipient. The protection will comprise only components present in the vaccine and homologous antigens.

In particular, Haemophilus influenzae B vaccine, influenzae vaccine, measles vaccine, Hepatitis A and B
20 vaccines, BCG (tuberculosis) vaccine, Diphteria vaccine, Tetanus vaccine, Meningoencephalitis vaccine, Japanese Encephalitis vaccine, Cholera vaccine, Rubella vaccine, Parotitis vaccine, Pneumococ vaccine, Polio vaccine, Rabies vaccine, Yellow fever vaccine, Thyphoid vaccine,
25 HIV vaccine, malaria vaccine as well as other vaccines against parasites, Herpes I and II, Bilharzioses vaccine may be of interest. Also, combination vaccines are may be of particular interest. Examples of such combination vaccines are Diphteria-Tetanus-Wooping cough-Polio
30 vaccine, Measles-Parotitis-Rubella vaccine, Hepatitis A and B vaccine.

Another example of an important field of application of the present invention is the field of allergy treatment,
35 including preventing and alleviating allergic reactions.

It is well known that genetically predisposed individuals become sensitised (allergic) to antigens originating from a variety of environmental sources, of which the individuals are exposed. The allergic reaction occurs
5 when a previously sensitised individual is re-exposed to the same or a homologous allergen. Allergic responses range from hay fever, rhinoconductivitis, rhinitis and asthma to systemic anaphylaxis and death in response to e.g. bee or hornet sting or insect bite. The reaction is
10 immediate and can be caused by a variety of atopic allergens such as compounds originating from grasses, trees, weeds, insects, (house dust) mites, food, drugs, chemicals and perfumes.

15 In order to eliminate the strong allergic reactions, carefully controlled and repeated injections with the allergen is commonly used in order to desensitise the patient. Such therapy, where allergic patients are exposed to the offending allergen until a maintenance
20 dose is reached, is usually continued for a long period of time once the maintenance level is reached. This means that specific allergy vaccination include more injections in numbers that a traditional vaccination scheme in healthy people.

25

Traditionally vaccination is performed by a priming dose, which after a certain period is followed by a boosting. For most vaccines, boosting has to be repeated every 5-10 years in order to maintain the immunological memory
30 intact.

Compared to other types of vaccination, allergy vaccination is complicated by the existence of an ongoing immune response in allergic patients. This immune
35 response is characterised by the presence of allergen-specific IgE, the primary effect of which is the release

of allergic symptoms upon exposure to allergens. Thus, allergy vaccination using allergens from natural sources has an inherent risk of side effects being in the utmost consequence life-threatening to the patient.

5

In accordance with the present invention, a method for the treatment, prevention or alleviation of allergic reactions comprising administering to a vertebrate, including a human being, a vaccine as defined herein is
10 envisaged.

The immunogenic substance may suitably be derived from inhalation allergens originating i.a. from trees, grasses, herbs, fungi, house dust mites, cockroaches and
15 animal hair and dandruff. Important pollen allergens from trees, grasses and herbs are such originating from the taxonomic orders of *Fagales*, *Oleales* and *Pinales* including i.a. birch (*Betula*), alder (*Alnus*), hazel (*Corylus*), hornbeam (*Carpinus*) and olive (*Olea*), the
20 order of *Poales* including i.a. grasses of the genera *Lolium*, *Phelum*, *Poa*, *Cynodon*, *Dactylis* and *Secale*, the orders of *Asterales* and *Urticales* including i.a. herbs of the genera *Ambrosia* and *Artemisia*. Important inhalation allergens from fungi are i.a. such originating from the
25 genera *Alternaria* and *Cladosporium*. Other important inhalation allergens are those from house dust mites of the genus *Dermatophagoides*, those from cockroaches and those from mammals such as cat, dog and horse. Further, recombinant allergens according to the invention may be
30 derived from venom allergens including such originating from stinging or biting insects such as those from the taxonomic order of Hymenoptera including bees, wasps, and ants.

35 It is to be understood that the term derived from includes the naturally-occurring substance as well as

isoforms thereof. Furthermore, the substance may be prepared by means of recombinant or synthetic techniques. Specific allergen components are known to the person skilled in the art and include e.g. *Bet v 1* (*B. verrucosa*, birch), *Aln g 1* (*Alnus glutinosa*, alder), *Cor a 1* (*Corylus avelana*, hazel) and *Car b 1* (*Carpinus betulus*, hornbeam) of the *Fagales* order. Others are *Cry j 1* (*Pinales*), *Amb a 1* and *2*, *Art v 1* (*Asterales*), *Par j 1* (*Urticales*), *Ole e 1* (*Oleales*), *Ave e 1*, *Cyn d 1*, *Dac g 1*, *Fes p 1*, *Hol l 1*, *Lol p 1* and *5*, *Pas n 1*, *Phl p 1* and *5*, *Poa p 1*, *2* and *5*, *Sec c 1* and *5*, and *Sor h 1* (various grass pollens), *Alt a 1* and *Cla h 1* (fungi), *Der f 1* and *2*, *Der p 1* and *2* (house dust mites, *D. farinae* and *D. pteronyssinus*, respectively), *Bla g 1* and *2*, *Per a 1* (cockroaches, *Blatella germanica* and *Periplaneta americana*, respectively), *Fel d 1* (cat), *Can f 1* (dog), *Equ c 1*, *2* and *3* (horse), *Apis m 1* and *2* (honeybee), *Ves g 1*, *2* and *5*, *Pol a 1*, *2* and *5* (all wasps) and *Sol i 1*, *2*, *3* and *4* (fire ant).

20

Furthermore, the present invention may be useful in veterinary applications. Examples are delivery of e.g. Luteinising Hormone Releasing Hormone (LHRH) (treatment or vaccination), allergy vaccination or treatment (e.g. fleas, house dust mites), treatment of health worm disease, foot and mouth disease, parasites, foot root, sneezing disease, rabies, pig plague, and vitamin deficiency or delivery. The animals to receive the compositions/formulations of the invention include cats, dogs, birds, poultry, cattle, sheep, horses, other fur-bearing domestic animals, and fish.

It is to be understood that the compositions, formulations, vaccines and mucosal delivery systems of the invention may further comprise adjuvants, excipients or other additives or ingredients suitable for such

formulations. Such adjuvants, excipients and other additives or ingredients are well-known to the person skilled in the art, and include i.a. solvents, emulsifiers, wetting agents, plastisizers, colouring substances, fillers, preservatives, viscosity adjusting agents, buffering agents, mucoadhesive and bioadhesive substances, and the like. Examples of formulation strategies are well-known to the person skilled in the art. Examples of mucoadhesive and bioadhesive substances are lectins, cellulose or acrylic polymers, chitosan and derivatives, natural gums and polycarylates.

In particular the following adjuvants may be used in the various products of the present invention: interleukins (e.g. IL-1 β , IL-2, IL-7, IL-12, INF γ), Adju-Phos[®], glucan, antigen formulation, Cholera Holotoxin, liposomes, DDE, DHEA, DMPC, DMPG, DOC/Alum Complex, Freund's incomplete adjuvant, ISCOMs[®], LT Oral Adjuvant, muramyl dipeptide, monophosphoryl lipid A, muramyl tripeptide, and phospatidylethanolamine (see also "Vaccine Design. The Subunit and Adjuvant Approach", Chapter 7 (ref. 8)).

Also, administration of the delivery system, the vaccine, or the formulation of the present invention may be combined with other procedures or routes, i.e. administration of the substance parenterally, or by another administration route. The order, sequence or interval of the administration can be varied arbitrarily.

In one embodiment of the invention the delivery system can be used to boost the response to a previously parenteral administered vaccination. The booster doses can preferably be administered (to the immune competent tissue in the nose, mouth, throat, or intestine) via the oral, buccal, sublingual, or nasal route.

The best patient compliance is believed to be obtained with administration via the oral route. The nasal route offers the smallest volumes to be administered, whereas
5 the buccal/sublingual route and the rectal route have intermediate properties. These routes, i.e. oral, nasal, buccal, sublingual and gastrointestinal, are therefore preferred.

10 The suitable amount of the biologically interactive substance to be administered depends on the substance in question, on the disease or condition to be treated, and further on the age, weight and state of the vertebrate in question. Finding the optimal dose will merely be a
15 matter of routine experimentation to the person skilled in the art.

It is also known to a person skilled in the art, that drugs administered via the mucosa generally have to
20 contain more than 100 times larger doses. Oral administration of birch allergen for vaccination purposes has shown, that the amount, which has to be used in order to obtain a clinical immune therapeutic effect was in 3 orders of magnitude of that used in the parenteral
25 treatment (Taudorf 1992 (ref. 11)). In consistence with other reports, EAACI position paper on local e.g. sublingual immunotherapy also show the use of very large doses (ref. 12). This is also the case for well known peptide drugs, e.g. for the peptide desmopressin
30 bioavailability is 1% after oral administration and 10% after nasal administration compared to the parenteral equivalent.

The delivery systems as provided herein allow obtaining
35 efficient response by oral administration with lower

amount of biological interactive substances than would be expected from the prior experiments.

5 The differences in dosing for mucosal versus parenteral route may be expected to vary greatly from substance to substance and route to route. The preferred doses are 0.1-100, most preferably 1-10 times as large as a parenteral bioequivalent dose.

10 In additional aspect, the present invention relates to a process for preparing a composition, a vaccine or a formulation as described herein by mixing a mucosal delivery system as described herein with a biologically interactive substance, optionally including one or more
15 pharmaceutically acceptable excipients. Thus, the invention also relates to a composition, a vaccine or a formulation as described herein obtainable by the process described herein.

20 An (aqueous) phase containing the biological interactive substance is formed by solution of the substance or by dilution of a more concentrated solution of this with water, optionally containing buffers, salts, solvents or excipients.

25 An (aqueous) suspension or gel of the oxygen-containing metal salt is formed by adding water, optionally containing buffer, salts, solvents or excipients, to a dry form of the oxygen-containing metal salt or
30 alternatively, optionally adding water containing buffer, salts, excipients, to a pre-equilibrated pre-formed gel.

The formulation is optionally made by combining one of these mixtures with a suitable amount of buffer phase,
35 optionally containing salts, solvents, or excipients, and adding the other mixture gradually at a controlled speed

under continued stirring or mixing to obtain a concentrated formulation containing a solid phase.

The concentrated formulation is left standing optionally
5 under agitation for a suitable time period.

This may then be filtered off, sedimented or optionally diluted by water, optionally containing buffer, salts, solvents or excipients to yield a final dosing
10 formulation.

Suitable buffers, salts, solvents, or excipients are preferably biologically acceptable, e.g. pharmaceutically acceptable that further are inert or inert amounts with
15 regard to destruction of the structure of the biologically interactive substance or the integrity of the structure of the oxygen-containing metal salt solid phase e.g. gel or the complex between these.

20 The present invention is further illustrated by the following non-limiting examples. By the examples, it is further envisaged that the biologically interactive substance is transported via a biomembrane as an immune response is observed. Cellular immune responses are
25 dependent on the one hand on the delivery via the mucosal membrane, and on the other hand on the availability of the substances to the macrophages and/or other antigen presenting cells. Thus, the efficacy of the present invention has been proved.

30

EXAMPLES

In the following, some general remarks regarding the experiments are given.

35

Animals

Mice were female BALB/c A mice from Bomholtgård, DK-8920 Ry, Denmark, being 6-8 weeks old at the start of the dosing period. They were housed in polycarbonate cages, 8 mice in each cage. Bedding was softwood sawdust. All
5 animals had access to food and water ad libitum. Food was a complete rodent diet from Chr. Petersen A/S, DK-4100 Ringsted, Denmark.

Animal control groups

10 Positive control groups: Immunisation by the intra-peritoneal route (i.p.) was used as a positive control, as this method is known to induce strong immune responses after a few injections.

15 Biologically interactive substances (immunogens):

Examples 1, and 5:

Tetanus toxoid (*T. toxoid*) (obtained from batches containing either 2.31 or 3.0 mg protein/ml, Statens Serum Institut, DK-2300 Copenhagen S, Denmark). Each dose
20 contained 30 µg *T. toxoid* in 0.25 ml.

Examples 2, 3, and 4:

P. pratense (Phl p) pollen extract (obtained from a batch obtained as described below with a protein content of
25 85.7% w/w, ALK-Abelló A/S, 2970-Hørsholm, Denmark). Each dose contained Phl p extract with a predetermined protein content of 50 µg in 0.25 ml equivalent to 100,000 Standardised Quality units (SQ)/ml.

30 Preparation of a *Phleum pratense* extract: Pollen from *Phleum pratense* (Allergon AB, Sweden or Biopol Inc., USA) were extracted in 1:10 w/v 0.5 M NaCl for 4 hours under gentle mixing at 3-8°C. The pollen was then removed by centrifugation and subsequent filtration through a 0.22
35 µm mesh. The clarified extract was then dialysed against

distilled water for 72 hours and freeze-dried (cf. also ref. 13).

Oxygen-containing metal salts:

- 5 The molar concentration stated below is for the final formulations.

Aluminium hydroxide, $\text{Al}(\text{OH})_3$ 0.045-0.05 M Al^{3+} (1.25 mg Al^{3+}/ml), or 0.04-0.045 M Al^{3+} (1.13 mg Al^{3+}/ml) in Example
10 3. Prepared from Alhydrogel 1.3%[®] (Superfos, DK-2950 Vedbæk, Denmark).

Calcium phosphate, $\text{Ca}_3(\text{PO}_4)_2$ 0.034 M Ca^{2+} . Prepared from Calcium Phosphate Adjuvant (Superfos, DK-2950 Vedbæk,
15 Denmark).

Aluminium phosphate, AlPO_4 0.05 M Al^{3+} . Prepared from Adju-phos[®] (Superfos, DK-2950 Vedbæk, Denmark).

20 Aluminium acetate, $\text{C}_4\text{H}_7\text{O}_5\text{Al}$ 0.05 M Al^{3+} . Prepared from aluminium acetate, basic (Sigma, USA).

Calcium tartrate, $\text{CaC}_4\text{H}_4\text{O}_6$ 0.05 M Ca^{2+} . Prepared from L-(+)-calcium tartrate hydrate (Sigma, USA).

25 Zinc sulphate, ZnSO_4 0.01 M Zn^{2+} . Prepared from zinc sulphate, heptahydrate (Sigma USA).

Preparation of the compositions/formulations/vaccines:

- 30 The test formulations/compositions/vaccines were prepared as follows:

The mucosal delivery systems for the delivery of a biologically interactive substance according to the
35 invention comprising an oxygen-containing metal salt were formed as described below.

Examples 1 and 2:

The immunogen (allergen extract or *Tetanus toxoid*) was dissolved or diluted to a concentration 10 times the concentration of the final formulation. 1/10 vol immunogen solution was mixed with 7/10 vol Coca 0.0 buffer (0.25% sodium hydrogen carbonate and 0.5% sodium chloride). 2/10 vol Alhydrogel® 1.3% was slowly added. In formulations for the control groups, receiving immunogens without Alhydrogel®, the Alhydrogel® was substituted with Coca 0.0 buffer.

These preparations were stored for no more than 3 weeks. Formulations comprising oxygen-containing metal salts and *T. toxoid* were stored at 4°C. All other formulations were stored at -22°C.

Examples 3, 4, and 5:

The immunogen (allergen extract or *T. toxoid*) was dissolved or diluted to a concentration 10 times the concentration of the final formulation. The metal salt were dissolved or diluted to a concentration five times the concentration of the final formulation with regard to the cation. 1/10 vol immunogen solution was slowly mixed with 2/10 vol metal salt, and left stirring over night at 4°C. The following day 7/10 vol Coca 0.0 buffer (0.25% sodium hydrogen carbonate and 0.5% sodium chloride) was slowly added.

In formulation for the control groups, receiving the metal salt without immunogen, the immunogen was substituted with Coca 0.0. buffer.

In formulations for the control groups, receiving immunogens without metal salt, the metal salt was substituted with Coca 0.0 buffer.

These preparations were stored for no more than 3 weeks. Formulations comprising oxygen-containing metal salts and *T. toxoid* were stored at 4°C. All other formulations were
5 stored at -22°C.

Dosing:

Examples 1, 2, 3, and 5:

- 10 Peroral (p.o.) administration: The animals were treated for two periods of each 14 days, separated by a 4 weeks period of rest. Thus, according to this, the animals were administered once daily day 0-13, rested day 14-41, and administered once daily day 42-55. The formulation/-
15 vaccine/composition 0.25 ml/dose (i.e. *T. toxoid* or *P. pratense*) were administered by oral gavage (direct delivery to the stomach). The mice were not anaesthetised when dosed.
- 20 Intraperitoneally (i.p.) administration: The animals received three doses at 14 days intervals (i.p.), 0.25 ml/dose. The mice were non-anaesthetised when dosed.

Example 4:

- 25 The animals were administered 0.25 ml subcutaneous (s.c.) or 0.25 ml either s.c. or p.o. formulation/vaccine/-composition according to Table 4.

Blood sampling:

- 30 Blood samples were drawn from the orbital vein and sera were analysed individually by ELISA.

ELISA

- Examples 1, 2 and 5 were performed as direct coated
35 ELISA. Examples 3 and 4 were performed as sandwich ELISA.

Plates:

Examples 1, 2, 3, 4, and 5:

MaxiSorp® F96, NUNC, Denmark.

- 5 All reagents described below were added in a total volume of 100 µl/well.

Antigen:

Examples 1 and 5:

- 10 *Tetanus toxoid* (*T. toxoid*) 10 µg protein/ml, (obtained from batch containing either 2.31 or 3.0 mg protein/ml, Statens Serum Institut, Copenhagen, Denmark).

Example 2:

- 15 Pollen extract from *Phleum pratense* (*P. pratense*) 3 µg protein/ml (obtained from a batch obtained as described below with a protein content of 85.7% w/w, ALK-Abelló A/S, Hørsholm, Denmark).

- 20 Examples 3 and 4:

1th layer: 3 µg/ml rabbit a-Ph1 p (ALK-Abelló A/S, Hørsholm, Denmark).

2nd layer: Ph1 p extract 30 µg/ml (obtained from batch with a protein content of 85.7% w/W, ALK-Abelló A/S,

- 25 Hørsholm, Denmark).

Positive controls:

Examples 1 and 5:

Protein A from monoclonal Tetanus IgG2a antibody

- 30 5.1G11E5E3 (Statens Serum Institut, Copenhagen, Denmark)

Examples 2, 3, and 4:

Serum pools from BALB/c A mice immunized i.p. with pollen extract from *P. pratense* (Bomholtgård, Ry, Denmark).

35

Negative controls:

Examples 1, and 2:

Serum pools from un-immunised BALB/c A mice 8 month old (Bomholtgård, Ry, Denmark).

5 Examples 3, 4, and 5:

Serum pools from un-immunised BALB/c A mice 4 month old (Bomholtgård, Ry, Denmark).

Secondary antibody:10 Examples 1, and 2:

Biotin anti-mouse IgG1 (Pharmingen, The Netherlands),
biotin anti-mouse IgG2a (Pharmingen, The Netherlands),
biotin rabbit anti-mouse Ig, P0260 (DAKO, Denmark).

15 Examples 3, 4, and 5:

Biotin anti-mouse IgG (Jackson ImmunoResearch Laboratories, USA)

Substrates:20 Examples 1, and 2:

Peroxidase conjugated streptavidin (DAKO, Denmark).

Examples 3, 4, and 5:

3,3',5',5'-Tetramethylbenzidine (TMB) (Sigma, USA)

25

Immunoreader:Examples 1, 2, 3, 4, and 5:

EL 340 Bio Kinetics Reader (Bio-Tek Instruments).

30 Analytical procedure:Examples 1, and 2:

Plates were coated overnight with the respective antigen. Serum samples from individual animals or control animals were added. The antibody-antigen reaction was allowed to

35 take place overnight. The following day, secondary

antibody and substrates were added. The plates were then read in an immunoreader at 470 nm.

Example 5:

- 5 As described under Examples 1, and 2, with the exception that the plates were blocked with bovine serum albumin before serum was added. The plates were read at 450 nm.

Examples 3, and 4:

- 10 Plates were coated overnight with the antibody. The antibody-antigen reaction in 1st and 2nd layer was allowed to take place for one hour. Serum samples were added. This antigen-antibody reaction was allowed to take place for two hours, followed by adding secondary antibody and
15 substrates. The plates were then read in an immunoreader at 470 nm.

Analysing sera for immunoglobulins:

Examples 1 and 2:

- 20 In order to examine the generated immune response, with regards to Th1/Th2 phenotype, the IgG subclasses were determined. IgG1 was chosen as a marker for a Th2 response, and IgG2a were chosen as a marker for a Th1 response.

25

All samples in Examples 1 and 2 were analysed for the presence of both IgG1 and IgG2a. ELISA dilution curves for these experiments are shown in Figures 1-24.

- 30 Specific Ig is determined by means of specific anti Ig.

Example 3, 4, and 5:

Blood samples were analysed for specific Ig.

- 35 The findings are further illustrated Tables 3-5 and Figures 25-27.

EXAMPLE 1

Immunisation with *Tetanus toxoid*

5 Immunisation with *T. toxoid* was performed p.o., or i.p. (control animals) as described above. Three test groups of 8 animals each were used. One group received oral doses of the antigen-aluminium hydroxide (0.045-0.05 M) formulation/composition/vaccine prepared as described
10 above. One group received oral doses of the antigen without the oxygen-containing metal salt-containing mucosal delivery system and one group (control animals) was immunised i.p. with the antigen-aluminium hydroxide (0.045-0.05 M) formulation/composition/vaccine as
15 described above. The results obtained are shown in Table 1 below.

Results are indicated as "number of positive responding mice/total number of mice in the group". "Ig tot."
20 indicates specific Ig.

Positive response

A response is considered positive if the OD-value of the serum is greater than the OD-value of a negative control
25 serum for at least two consecutive dilutions.

The results are depicted in Figures 1-18.

TABLE 1

	P.o. T. toxoid and aluminium hydroxide			P.o. T. toxoid without aluminium hydroxide			I.p. T. toxoid		
	Ig tot.	Ig G1	Ig G2a	Ig tot.	Ig G1	Ig G2a	Ig tot.	Ig G1	Ig G2a
T. toxoid Day 35		4/8	3/8		4/8	1/8		8/8	8/8
T. toxoid Day 56		5/8	4/8		1/8	1/8		8/8	8/8
T. toxoid Day 70	6/8	7/8	4/8	2/8	2/8	1/8	8/8	8/8	8/8

As can be seen from Table 1 and Figures 1-18, the number of positive responding mice (day 70) with levels of specific Ig seen with p.o. immunisation is comparable to the number of positive responding mice observed for i.p. immunisation.

Furthermore, the phenotype of response (IgG1 and IgG2a) indicate both Th₁ and Th₂ responses.

In conclusion, Example 1 shows the feasibility of using the invention for oral vaccination, the immunogenic substance being exemplified by *T. toxoid*, and the mucosal delivery system being exemplified by aluminium hydroxide.

The finding that an immune response is observed, furthermore, indicates that it is possible to use the invention to deliver a biologically interactive substance via the mucosal membrane.

EXAMPLE 2

Immunisation with *P. pratense*

Immunisation was performed with the allergen from *P. pratense*, as described above. Three test groups of 8 animals each were used. One group received oral doses of the antigen formulated with aluminium hydroxide-containing mucosal delivery system, prepared as described above. One group received oral doses of the antigen without the oxygen-containing metal salt-containing delivery system, and one group was immunised i.p with the antigen-aluminium hydroxide formulation/vaccine, as described above. The results obtained are shown in Table 2 below. Results are indicated as "number of positive responding mice/total number of mice in the group". "Ig tot." indicates specific Ig.

Positive response

A response is considered positive if the OD-value of the serum is greater than OD-value of a negative control serum for at least two consecutive dilutions.

The results are further visualised in Figures 19-24.

TABLE 2

25

	P.o. Phl p and aluminium hydroxide			P.o. Phl p without aluminium hydroxide			I.p. Phl 1		
	Ig tot.	Ig G1	Ig G2a	Ig tot.	Ig G1	Ig G2a	Ig tot.	Ig G1	Ig G2a
Phl p Day 70	7/8	4/8	2/8	2/8	2/8	1/8	8/8	8/8	8/8

Table 2 shows the number of mice (day 70) with levels of specific Ig in sera following p.o. immunisation with Phl p with or without aluminium hydroxide-containing mucosal delivery system. The number of positively responding mice
5 is comparable to the number of positive responding mice observed following i.p. immunisation.

Furthermore, the type of response (IgG1 and IgG2a) corresponds to that observed with i.p. immunisation.
10 Thus, it is seen that the vaccination in accordance with the invention gives raise to an immunised state similar to that obtained with i.p. vaccination.

In conclusion, Example 2 shows the feasibility of the
15 present invention for allergy vaccination, the immunogenic substance being exemplified by *Phleum pratense*, and the oxygen-containing metal salt being exemplified by aluminium hydroxide.

20 The results shown in Table 2 furthermore show the uptake via the mucosal membrane of an intact immunogen and subsequent presentation to the relevant cells (B-cells) in a form which retains its three-dimensional structure. Delivery of a biologically interactive substance with an
25 essentially conserved three-dimensional structure is believed to be necessary for a B-cell dependent antibody response. Delivery through the gastrointestinal tract, using other delivery systems, usually induces denaturation of large proteins and peptides and
30 subsequently destroys the three-dimensional structure and the B-cell epitopes, a phenomenon well known for grass allergens (cf. e.g. ref. 11).

EXAMPLE 3

35

Immunisation with *Phleum pratense*

Immunisation was carried out with Phl p in two different formulations containing an aluminium hydroxide-containing mucosal delivery system. Four test groups, of 8 animals each, were used. One group received Phl p in a formulation containing 1.13 mg Al/ml aluminium hydroxide prepared as described above. One group received Phl p in a formulation containing 1.25 mg Al/ml aluminium hydroxide prepared as described above. Control groups received the same amount of the oxygen-containing metal salt-containing mucosal delivery system formulation, 1.13 mg Al/ml and 1.25 mg Al/ml without allergen in parallel. Results are indicated as "number of positively responding mice/total number of mice in the group".

15 Positive response:

A response is considered positive if the OD-value of the serum is greater than the OD-value of a negative control serum for at least two consecutive dilutions.

20 TABLE 3

Formulation of aluminium hydroxide	Route of adm.	Response
1.25 mg/ml + Phl. p. Day 70	p.o.	5/8
1.25 mg/ml Day 70	p.o.	1/8
1.13 mg/ml + Phl.p. Day 70	p.o.	6/8
1.13 mg/ml Day 70	p.o.	1/4

In conclusion, Example 3 shows that various formulations containing different concentrations of the oxygen-containing metal salt can be applied. The concentration

of metal salt may be subject to optimisation. In this example, the immunogenic substance is exemplified by *P. pratense*, and the oxygen-containing metal salt is exemplified by aluminium hydroxide, used in two different concentrations.

EXAMPLE 4

Immunisation with *Phleum pratense* using different administration protocols

Immunisation was performed with the allergen from *P. pratense*.

Three groups, of 8 mice each, were immunised according to Table 4 and as described under "Dosing" above.

Positive response:

Sera from groups of mice were analysed individually and the dilution curves obtained are illustrated by a OD-reading for each dilution (Figures 25-27). On top of the points measured, a line illustrating the geometric mean for the group is applied. Two lines obtained from the positive controls are illustrated on each figure due to the fact that a group of eight mice were analysed on two ELISA plates. A response is considered positive if there is a significant difference in the OD response in the same dilution from sera analysed for groups of mice dosed differently.

The results are further visualised in Figures 25-27.

TABLE 4

Group	Route of adm.	Time of dosing	Vaccine formulation
1 s.c.x4	s.c. s.c.	dag 0 dag 21, 22, 23	Aluminium hydroxide and Phl p
2 s.c.x1 + p.o.x3 active	s.c. p.o.	dag 0 dag 21, 22, 23	Aluminium hydroxide and Phl p
3 s.c.x1 + x3 placebo	s.c. p.o.	dag 0 dag 21, 22, 23	Aluminium hydroxide without Phl p Placebo

From comparison of the Figures 25-27 it can be seen that group 2 has a significant higher number of positive responding mice than group 3. Group 1 is included as a positive control and therefore has a significant higher number of positive responding mice than group 2 and 3.

In conclusion, Example 4 shows that by combining different routes of administration it may be possible to induce a strong immune response with active but not with placebo formulations. Furthermore, it may be possible to induce a response that has an earlier debut, higher diagnostic level and/or is very consistent.

The invention may e.g. be used for giving booster immunisations, when applied in combination with conventional vaccination regimes. Alternatively, different administration routes may advantageously be used to improve the vaccination.

In this example, the biologically interactive substance is exemplified by *P. pratense*, and the oxygen-containing metal salt is exemplified by aluminium hydroxide.

5

EXAMPLE 5

Immunisation with *Tetanus toxoid* using different oxygen-containing metal salts in the mucosal delivery system

10 The immunisation was performed using *T. toxoid* formulated with different oxygen-containing metal salts (cf. above) as constituent of the mucosal delivery system. 22 groups, each of 8 mice, were immunised according to the protocol described above. 6 different oxygen-containing metal
15 salts were used and the formulations were chosen as molar amount of the cation equivalent to 1.25 mg/ml aluminium hydroxide. All oxygen-containing metal salts were formulated with *T. toxoid*, as described previously. The procedures could probably be further optimised i.a. with
20 regard to reaction times, relative concentrations, and/or pH.

Positive response:

A response is considered positive if the OD value,
25 measured in sera drawn on day 70 (p.o.) or day 35 (i.p.), is at least 0.5 absorption unit larger than the corresponding signal measured for the negative control group.

30

TABLE 5

Oxygen- containing metal salt	P.o. T.toxoid in MDS IgG Day 70	P.o. T.toxoid without MDS IgG Day 70	P.o. MDS without T.toxoid IgG Day 70	I.p. T.toxoid in MDS IgG Day 35
$\text{Ca}_3(\text{PO}_4)_2$	5/7	1/8	0/8	8/8
AlPO_4	8/8		0/8	8/8
ZnSO_4	3/8	1/8	0/8	8/8
$\text{Al}(\text{OH})_3$	7/8	0/8	0/8	8/8
$\text{CaC}_4\text{H}_4\text{O}_6$	7/8	0/8	0/8	7/7
$\text{Al}(\text{OH})(\text{CH}_3\text{COO})_2$	6/8		0/8	8/8

MDS means mucosal delivery system.

- 5 As can be seen from Table 5 all groups immunised with the antigen formulated to an oxygen-containing metal salt induce an immune response in a larger number of mice than the control groups immunised with either antigen without oxygen-containing metal salt or oxygen-containing metal salt without antigen. All compositions/formulations/-
10 vaccines induce a consistent immune response when used i.p.

In conclusion, Example 5 shows that a wide range of
15 oxygen-containing metal salts can effectively induce an immune response, when used in a mucosal delivery system according to the invention. In this example, the immunogenic substance is exemplified by *T. toxoid* and the metal salt is exemplified by aluminium hydroxide, calcium phosphate, aluminium phosphate, zinc sulphate, calcium
20 tartrate and aluminium acetate, respectively.

REFERENCES

1. WO 94/21288 (Assay Research, Inc.)
- 5 2. WO 95/05194 (Medeva Holdings B.V.)
3. JP 65008152 B (Abstract) (Yaoi, H.)
4. GB 2 195 996 (Mitsui Norin Company Limited)
- 10 5. GB 1 078 879 (Parke, Davis & Company)
6. FR 2 143 588 (Herman Schettler)
- 15 7. P.M. Callahan et al., Pharmaceutical Research Vol. 8, No. 7, 851-858 (1991)
8. "Vaccine Design. The Subunit and Adjuvant Approach", Chapters 7, 8 and 9, Ed. M.F. Powell & M.J. Newman
- 20 (1995), Plenum Press
9. EP 266 119 (Southern Research Institute, and The UAB Research Foundation)
- 25 10. The Handbook of Chemistry and Physics 56 Ed., Section B, Chapter 7 (1975-1976)
11. E. Taudorf: "Oral Immunotherapy", Doctorate Thesis, 1992, Lægeforeningens Forlag, Copenhagen, Denmark
- 30 12. EAACI position paper: "Local immunotherapy", 1998, EAACI Immunotherapy Subcommittee and the ESPACI Immunotherapy Committee
- 35 13. Ipsen & Løwenstein, The Journal of Allergy and Clinical Immunology, Vol. 72, No. 2, 150-159 (1983)

CLAIMS:

1. Composition for the delivery of an immunogenic substance via a mucosal membrane of a vertebrate
5 comprising
 (1) at least one immunogenic substance which is a natural, recombinant or modified allergen or allergoid, and
 (2) a mucosal delivery system comprising at least one
10 oxygen-containing metal salt which is aluminium hydroxide, aluminium phosphate, aluminium sulphate, aluminium acetate, potassium aluminium sulphate, calcium phosphate, calcium tartrate, Maalox, beryllium hydroxide, zinc hydroxide, zinc carbonate, barium sulphate or zinc
15 sulphate.
2. Composition according to claim 1, wherein the oxygen-containing metal salt is aluminium hydroxide, aluminium phosphate, calcium phosphate, calcium tartrate or zinc
20 sulphate.
3. Composition according to claim 1 or 2, wherein the immunogenic substance is an allergen.
- 25 4. A composition according to any one of claims 1-3 wherein the immunogenic substance is an inhalant allergen or a venom allergen.
5. Composition according to any one of claims 1-4 further
30 comprising a bioadhesive.
6. Composition according to any one of claims 1-5 further comprising a pharmaceutically acceptable adjuvant.
- 35 7. Composition according to claim 6 wherein said adjuvant is an interleukin, glucan, antigen formulation, Cholera

Holotoxin, liposome, DDE, DHEA, DMPC, DMPG, DOC/Alum Complex, Freund's incomplete adjuvant, LT Oral Adjuvant, muramyl dipeptide, monophosphoryl lipid A, muramyl tripeptide, or phospatidylethanolamine.

5

8. Composition according to any one of claims 1-7 in a form suitable for oral, nasal, vaginal, sublingual, ocular, rectal, urinal, intramammal, pulmonal, otolar, or buccal administration

10

9. Composition according to any one of claims 1-8, wherein the mucosal membrane is a nasal mucosal membrane, buccal mucosal membrane, a sublingual mucosal membrane, or a gastrointestinal mucosal membrane.

15

10. Vaccine for the delivery of an immunogenic substance via a mucosal membrane of a vertebrate comprising

(1) at least one immunogenic substance which is a natural, recombinant or modified allergen or allergoid, and

20

(2) mucosal delivery system comprising at least one oxygen-containing metal salt which is aluminium hydroxide, aluminium phosphate, aluminium sulphate, aluminium acetate, potassium aluminium sulphate, calcium phosphate, calcium tartrate, Maalox, beryllium hydroxide, zinc hydroxide, zinc carbonate, barium sulphate or zinc sulphate.

25

11. Vaccine according to claim 10, wherein the oxygen-containing metal salt is aluminium hydroxide, aluminium phosphate, calcium phosphate, calcium tartrate or zinc sulphate.

30

12. Vaccine according to claim 10 or 11, wherein the immunogenic substances is an allergen.

35

13. A composition according to any one of claims 10-12 wherein the immunogenic substance is an inhalant allergen or a venom allergen.

5 14. Vaccine according to any one of claims 10-13 further comprising a bioadhesive.

15. Vaccine according to any one of claims 10-14 further comprising a pharmaceutically acceptable adjuvant.

10

16. Vaccine according to claim 15 wherein said adjuvant is an interleukin, glucan, antigen formulation, Cholera Holotoxin, liposome, DDE, DHEA, DMPC, DMPG, DOC/Alum Complex, Freund's complete adjuvant, LT Oral Adjuvant, 15 muramyl dipeptide, monophosphoryl lipid A, muramyl tripeptide, or phospatidylethanolamine.

17. Vaccine according to any one of claims 10-16 in the form of a spray, an aerosol, a mixture, tablets, capsule, 20 a suspension, a dispersion, granules, a powder, a solution, an emulsion, chewable tablets, tablets for dissolution, drops, a gel, a paste, a syrup, a cream, a lozenge, an instillation fluid, a gas, a vapour, an ointment, a stick, implants, intramammary preparations, 25 vagitories, suppositories, or uteritories.

18. Vaccine according to any one of claims 10-17 in a form suitable for oral, nasal, vaginal, sublingual, ocular, rectal, urinal, intramammal, pulmonal, otolar, or 30 buccal administration.

19. Vaccine according to any one of claims 10-18, wherein the mucosal membrane is a nasal mucosal membrane, buccal mucosal membrane, a sublingual mucosal membrane, or a 35 gastrointestinal mucosal membrane.

20. Mucosal delivery system for delivery via a mucosal membrane of a vertebrate of a immunogenic substance which is a natural, recombinant or modified allergen or allergoid, wherein said delivery system comprises at least one oxygen-containing metal salt which is aluminium hydroxide, aluminium phosphate, aluminium sulphate, aluminium acetate, potassium aluminium sulphate, calcium phosphate, calcium tartrate, Maalox, beryllium hydroxide, zinc hydroxide, zinc carbonate, barium sulphate or zinc sulphate.

21. Mucosal delivery system according to claim 20, wherein the oxygen-containing metal salt is aluminium hydroxide, aluminium phosphate, calcium phosphate, calcium tartrate or zinc sulphate.

22. Mucosal delivery system according to claim 20 or 21, wherein the immunogenic substance is an allergen.

23. Mucosal delivery system according to any one of claims 20-22 wherein the immunogenic substance is an inhalant allergen or a venom allergen.

24. Mucosal delivery system according to any one of claims 20-23, further comprising a bioadhesive.

25. Mucosal delivery system according to any one of claims 19-21 further comprising a pharmaceutically acceptable adjuvant.

26. Mucosal delivery system according to claim 25 wherein said adjuvant is an interleukin, glucan, antigen formulation, Cholera Holotoxin, liposomes, DDE, DHEA, DMPC, DMPG, DOC/Alum Complex, Freund's incomplete adjuvant, LT Oral Adjuvant, muramyl dipeptide,

monophosphoryl lipid A, muramyl tripeptide, or phospatidylethanolamine.

27. Mucosal delivery system according any one of claims
5 20-23 in the form of a spray, an aerosol, a mixture, tablets, capsule, a suspension, a dispersion, granules, a powder, a solution, an emulsion, chewable tablets, tablets for dissolution, drops, a gel, a paste, a syrup, a cream, a lozenge, an instillation fluid, a gas, a
10 vapour, an ointment, a stick, implants, intramammary preparations, vagitories, suppositories, or uteritories.

28. Mucosal delivery system according to any one of claims 20 to 23 formulated for oral, nasal, vaginal,
15 sublingual, ocular, rectal, urinal, intramammal, pulmonal, otolar, or buccal administration.

29. Mucosal delivery system according to any one of claims 20 to 27, wherein the mucosal membrane is a nasal
20 mucosal membrane, buccal mucosal membrane, a sublingual mucosal membrane, or a gastrointestinal mucosal membrane.

30. Process for preparing a composition according to any one of claims 1-9 or vaccine according to any one of
25 claims 10-19 by mixing a mucosal delivery system according to any one of claims 20-29 with a immunogenic substance which is (i) a natural, recombinant or modified allergen, or (ii) an allergoid, and optionally pharmaceutically acceptable excipients.

30

31. Use of a composition according to any one of claims 1-9, a vaccine according to any one of claims 10-19 or a mucosal delivery system according to any one of claims 20-29 for the manufacture of a medicament for the
35 mucosal treatment, prevention or alleviation of allergic reactions.

32. Use according to claim 31 of a composition comprising

- 5 (1) at least one immunogenic substance which is a natural, recombinant or modified allergen or an allergoid, and
- (2) a mucosal delivery system comprising at least one oxygen-containing metal salt which is aluminium
- 10 hydroxide, aluminium phosphate, aluminium sulphate, aluminium acetate, potassium aluminium sulphate, calcium phosphate, calcium tartrate, Maalox, beryllium hydroxide, zinc hydroxide, zinc carbonate, barium sulphate or zinc sulphate for the manufacture of a medicament for the
- 15 mucosal treatment, prevention or alleviation of allergic reactions.

33. Use of an composition according to any one of claims 1-9, a vaccine according to any one of claims 10-19 or a

20 mucosal delivery system according to any one of claims 20-29 for the manufacture of a medicament for the buccal, sublingual, nasal or intestinal treatment, prevention or alleviation of allergic reactions.

25 34. Use according to claim 33 of a composition comprising

- (1) at least one immunogenic substance which is a natural, recombinant or modified allergen or an allergoid, and
- 30 (2) a mucosal delivery system comprising at least one oxygen-containing metal salt which is aluminium hydroxide, aluminium phosphate, aluminium sulphate, aluminium acetate, potassium aluminium sulphate, calcium phosphate, calcium tartrate, Maalox, beryllium hydroxide,
- 35 zinc hydroxide, zinc carbonate, barium sulphate or zinc sulphate for the manufacture of a medicament for the

buccal, sublingual, nasal or intestinal treatment, prevention or alleviation of allergic reactions.

35. Use according to any one of claims 31-34 for the
5 manufacture of a vaccine for specific allergy vaccination treatment or prevention.

36. Use of a composition according to any one of claims
1-9, a vaccine according to any one of claims 10-19 or a
10 mucosal delivery system according to any one of claims 20-29 as an agent for prevention or alleviation of allergic reactions.

37. Use according to claim 36 of a composition comprising
15

(1) at least one immunogenic substance which is a natural, recombinant or modified allergen or allergoid, and

(2) a mucosal delivery system comprising at least one
20 oxygen-containing metal salt which is aluminium hydroxide, aluminium phosphate, aluminium sulphate, aluminium acetate, potassium aluminium sulphate, calcium phosphate, calcium tartrate, Maalox, beryllium hydroxide, zinc hydroxide, zinc carbonate, barium sulphate or zinc
25 sulphate, in a form suitable for mucosal membrane delivery, as an agent for prevention or alleviation of allergic reactions.

38. Use of a composition according to any one of claims
30 1-9, a vaccine according to any one of claims 10-19 or a mucosal delivery system according to any one of claims 20-29 in a form suitable for buccal, sublingual, nasal or intestinal delivery, as an agent for alleviation of allergic reactions.

39. Use according to claim 38 wherein said composition comprises

(1) at least one immunogenic substance which is a
5 natural, recombinant or modified allergen or allergoid,
and

(2) a mucosal delivery system comprising at least one
oxygen-containing metal salt which is aluminium
hydroxide, aluminium phosphate, aluminium sulphate,
10 aluminium acetate, potassium aluminium sulphate, calcium
phosphate, calcium tartrate, Maalox, beryllium hydroxide,
zinc hydroxide, zinc carbonate, barium sulphate or zinc
sulphate.

15 40. Use according to any one of claims 36-39 as a vaccine
for specific allergy vaccination treatment or prevention.

1/27

IgG1 response on day 35
for mice immunised p.o. with
Tetanus toxoid suspended with Alhydrogel®




Figure 1

2/27

IgG1 response on day 35
for mice immunised p.o. with
Tetanus toxoid without Alhydrogel®




Figure 2

3/27

IgG1 response on day 35
for mice immunised i.p. with
Tetanus toxoid (control group)




Figure 3

4/27

IgG2a response on day 35
for mice immunised p.o. with
Tetanus toxoid suspended with Alhydrogel®




Figure 4

5/27

IgG2a response on day 35
for mice immunised p.o. with
Tetanus toxoid without Alhydrogel®




Figure 5

6/27




Figure 6

IgG1 response on day 56
for mice immunised p.o. with
Tetanus toxoid suspended with Alhydrogel[®]




Figure 7

IgG1 response on day 56
for mice immunised p.o. with
Tetanus toxoid without Alhydrogel®

8/27




Figure 8

9/27

IgG1 response on day 56
for mice immunised i.p. with
Tetanus toxoid (control group)




Figure 9

IgG2a response on day 56
for mice immunised p.o. with
Tetanus toxoid suspended with Alhydrogel®




Figure 10

IgG2a response on day 56
for mice immunised p.o. with
Tetanus toxoid without Alhydrogel[®]




Figure 11

IgG2a response on day 56
for mice immunised i.p. with
Tetanus toxoid (control group)




Figure 12

IgG1 response on day 70
for mice immunised p.o. with
Tetanus toxoid suspended with Alhydrogel®




Figure 13

IgG1 response on day 70
for mice immunised p.o. with
Tetanus toxoid without Alhydrogel®




Figure 14

IgG1 response on day 70
for mice immunised i.p. with
Tetanus toxoid (control group)




Figure 15

IgG2a response on day 70
for mice immunised p.o. with
Tetanus toxoid suspended with Allhydrogel®




Figure 16




Figure 17

IgG2a response on day 70
for mice immunised i.p. with
Tetanus toxoid (control group)




Figure 18

IgG1 response on day 70
for mice immunised p.o. with
Phleum pratense suspended with Alhydrogel®




Figure 19




Figure 20

21/27

IgG1 response on day 70
for mice immunised i.p. with
Phleum pratense (control group)




Figure 21

22/27

IgG2a response on day 70
for mice immunised p.o. with
Phleum pratense suspended with Alhydrogel®




Figure 22

23/27

IgG2a response on day 70
for mice immunised p.o. with
Phleum pratense without Allhydrogel®




Figure 23

IgG2a response on day 70
for mice immunised i.p. with
Phleum pratense (control group)




Figure 24

Figure 25 Phl p, s.c. x4




Figure 26 Phl p, s.c. x 1 + p.o x 3




Figure 27 Phl p s.c. x 1 + Placebo p.o. x 3

